Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

William W. Hope, Peter A. Warn, Andrew Sharp, Paul Reed, Brian Keevil, Arnold Louie, Thomas J. Walsh, David W. Denning, George L. Drusano

Research output: Contribution to journalArticle

Abstract

Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

Original languageEnglish (US)
Pages (from-to)3760-3762
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume51
Issue number10
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Flucytosine
Candidiasis
Amphotericin B
Body Weight

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis : A pharmacodynamic rationale for reduced dosing. / Hope, William W.; Warn, Peter A.; Sharp, Andrew; Reed, Paul; Keevil, Brian; Louie, Arnold; Walsh, Thomas J.; Denning, David W.; Drusano, George L.

In: Antimicrobial Agents and Chemotherapy, Vol. 51, No. 10, 10.2007, p. 3760-3762.

Research output: Contribution to journalArticle

Hope, William W. ; Warn, Peter A. ; Sharp, Andrew ; Reed, Paul ; Keevil, Brian ; Louie, Arnold ; Walsh, Thomas J. ; Denning, David W. ; Drusano, George L. / Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis : A pharmacodynamic rationale for reduced dosing. In: Antimicrobial Agents and Chemotherapy. 2007 ; Vol. 51, No. 10. pp. 3760-3762.
@article{853890703f064e79ae3a140f80a32bc3,
title = "Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing",
abstract = "Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.",
author = "Hope, {William W.} and Warn, {Peter A.} and Andrew Sharp and Paul Reed and Brian Keevil and Arnold Louie and Walsh, {Thomas J.} and Denning, {David W.} and Drusano, {George L.}",
year = "2007",
month = "10",
doi = "10.1128/AAC.00488-07",
language = "English (US)",
volume = "51",
pages = "3760--3762",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis

T2 - A pharmacodynamic rationale for reduced dosing

AU - Hope, William W.

AU - Warn, Peter A.

AU - Sharp, Andrew

AU - Reed, Paul

AU - Keevil, Brian

AU - Louie, Arnold

AU - Walsh, Thomas J.

AU - Denning, David W.

AU - Drusano, George L.

PY - 2007/10

Y1 - 2007/10

N2 - Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

AB - Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

UR - http://www.scopus.com/inward/record.url?scp=34948813009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948813009&partnerID=8YFLogxK

U2 - 10.1128/AAC.00488-07

DO - 10.1128/AAC.00488-07

M3 - Article

C2 - 17682101

AN - SCOPUS:34948813009

VL - 51

SP - 3760

EP - 3762

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -